Applied DNA Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Applied DNA SciencesDer Gewinn des Unternehmens wird voraussichtlich um 51.9% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 37.5% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 91.5% pro Jahr wachsen.

Wichtige Informationen

-51.9%

Wachstumsrate der Gewinne

91.5%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	18.4%
Wachstumsrate der Einnahmen	37.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	22 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%

Dec 20

Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Aug 17

Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise

Aug 09

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:APDN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
9/30/2025	5	-13	N/A	N/A	2
9/30/2024	4	-7	N/A	N/A	2
6/30/2024	3	-8	-14	-13	N/A
3/31/2024	6	-13	-12	-11	N/A
12/31/2023	9	-7	-9	-8	N/A
9/30/2023	13	-10	-7	-6	N/A
6/30/2023	16	-7	-7	-7	N/A
3/31/2023	18	-5	-8	-7	N/A
12/31/2022	19	-7	-8	-8	N/A
9/30/2022	18	-8	-9	-9	N/A
6/30/2022	18	-12	-12	-10	N/A
3/31/2022	15	-15	-12	-10	N/A
12/31/2021	12	-14	-15	-13	N/A
9/30/2021	9	-14	-16	-13	N/A
6/30/2021	6	-14	-14	-12	N/A
3/31/2021	5	-14	-16	-13	N/A
12/31/2020	3	-15	-14	-13	N/A
9/30/2020	2	-13	-12	-11	N/A
6/30/2020	3	-10	-10	-10	N/A
3/31/2020	5	-9	-8	-8	N/A
12/31/2019	5	-8	-8	-8	N/A
9/30/2019	5	-9	-7	-7	N/A
6/30/2019	5	-11	-8	-8	N/A
3/31/2019	4	-12	-8	-7	N/A
12/31/2018	4	-12	-6	-6	N/A
9/30/2018	4	-12	-7	-7	N/A
6/30/2018	4	-11	-6	-5	N/A
3/31/2018	5	-11	N/A	-6	N/A
12/31/2017	4	-12	N/A	-8	N/A
9/30/2017	5	-13	N/A	-7	N/A
6/30/2017	5	-12	N/A	-9	N/A
3/31/2017	4	-13	N/A	-9	N/A
12/31/2016	4	-13	N/A	-9	N/A
9/30/2016	4	-12	N/A	-10	N/A
6/30/2016	7	-10	N/A	-9	N/A
3/31/2016	8	-9	N/A	-8	N/A
12/31/2015	9	-7	N/A	-7	N/A
9/30/2015	9	-12	N/A	-7	N/A
6/30/2015	6	-13	N/A	-7	N/A
3/31/2015	4	-14	N/A	-8	N/A
12/31/2014	3	-15	N/A	-9	N/A
9/30/2014	3	-13	N/A	-9	N/A
6/30/2014	3	-15	N/A	-8	N/A
3/31/2014	3	-15	N/A	-8	N/A
12/31/2013	2	-15	N/A	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: APDN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: APDN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: APDN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: APDNDie Einnahmen des Unternehmens (37.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: APDNDie Einnahmen des Unternehmens (37.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von APDN in 3 Jahren voraussichtlich hoch sein wird

Applied DNA Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 20%

Consensus EPS estimates upgraded to US$5.32 loss

Consensus estimates of losses per share improve by 24%

Consensus EPS estimates upgraded to US$0.65 loss, revenue downgraded

Consensus revenue estimates fall by 49%

Consensus revenue estimates decrease by 13%, EPS upgraded

Recent updates

Applied DNA Sciences, Inc. Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Applied DNA Sciences, Inc. announced that it has received funding

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.499893 million.

New major risk - Market cap size

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc.'s Applied DNA Clinical Labs, LLC Launches Mpox Clade I and Clade II Testing Service

Applied DNA Sciences, Inc. to Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I

Consensus revenue estimates fall by 20%

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Applied DNA Sciences, Inc. to Report Q3, 2024 Results on Aug 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Sep 30, 2024

Applied DNA Sciences Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Consensus EPS estimates upgraded to US$5.32 loss

Applied DNA Sciences, Inc. Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health

Applied DNA Sciences, Inc. has completed a Composite Units Offering in the amount of $12 million.

New major risk - Share price stability

New major risk - Financial position

New major risk - Shareholder dilution

Consensus estimates of losses per share improve by 24%

Applied DNA Sciences, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering.

Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress

Consensus EPS estimates upgraded to US$0.65 loss, revenue downgraded

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Applied DNA Sciences, Inc. to Report Q1, 2024 Results on Feb 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Apr 15, 2024

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.436992 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.437233 million.

The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%

Consensus revenue estimates fall by 49%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Applied DNA Sciences Receives Non-Compliance Notice From Nasdaq

Applied DNA Sciences, Inc. to Report Q4, 2023 Results on Dec 07, 2023

Applied DNA Sciences, Inc. Extends Application of Linea(Tm) Ivt Platform to Sna (Self-Amplifying Mrna)

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs

Applied DNA Sciences, Inc. Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit

Applied DNA Sciences, Inc. Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Applied DNA Sciences, Inc. to Report Q3, 2023 Results on Aug 10, 2023

Applied DNA Sciences, Inc., Annual General Meeting, Sep 19, 2023

New minor risk - Share price stability

Applied DNA Sciences, Inc. (NasdaqCM:APDN) acquired Spindle Biotech Inc. for $2.8 million.

Consensus revenue estimates decrease by 13%, EPS upgraded

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Applied DNA Sciences, Inc. to Report Q2, 2023 Results on May 11, 2023

Consensus revenue estimates increase by 12%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Applied DNA Sciences, Inc. to Report Q1, 2023 Results on Feb 09, 2023

Applied DNA Sciences, Inc. Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA as New Class of DNA-Based Vaccines

Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Invest In Growth?

Consensus revenue estimates fall by 20%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Price target decreased to US$7.00

Applied DNA Sciences, Inc. to Report Q4, 2022 Results on Dec 05, 2022

Applied DNA climbs 51% after winning large purchase order

Applied DNA Sciences, Inc.'s Subsidiary, Applied DNA Clinical Labs, LLC, Launches Monkeypox Testing Service

Applied DNA stock rises 12% on launching monkeypox testing service in New York

Applied DNA Submits PCR-Based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health

Applied DNA adds 17% as company seeks approval for monkeypox test in New York

Consensus estimates of losses per share improve by 19%

Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations